



## Causes, Consequences, Challenges and Opportunities of Tumor Angiogenesis

Guest Editors:

**Dr. Laura Evangelista**

Department of Nuclear Medicine,  
Humanitas University, Pieve  
Emanuele, 20072 Milan, Italy

**Prof. Dr. Luigi Mansi**

Section Health and  
Development, Interuniversity  
Research Center for  
Sustainability (CIRPS), 00038  
Rome, Italy

Deadline for manuscript  
submissions:

**closed (15 December 2023)**

### Message from the Guest Editors

Neoangiogenesis is essential for the growth of tumors, mainly in the case of solid and undifferentiated cancers. Magnetic resonance imaging (MRI) with contrast enhancement (ce) and new radiopharmaceutical agents for PET imaging can be useful to detect and also to monitor this pathophysiological process. This Special Issue aims to:

- Define the role of MRI with ce and the role of other imaging technologies in evaluating the neoangiogenesis.
- Assess the advantages of new radiopharmaceutical agents for monitoring the evaluation of response to new targeted therapies in tumors.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)